News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jolt Health Inc. Terminates Acquisition Agreement and Shifts Focus to AI Opportunities
Jolt Health Inc. terminates acquisition of transdermal delivery technology for chloroquine and hydroxychloroquine, focusing on AI opportunities in healthcare and biotechnology. CEO Gerald Tritt emphasizes value of AI technology and growth initiatives -